Stock Price

The hormone optimization leader's stock tumbles after Q2 results show a net loss and declining revenue, revealing the prolonged impact of its January recall.

As Flowers Foods preps its Q2 results amid a plummeting stock price, the bakery giant's strategic pivot towards health trends and fiscal discipline faces a critical test.

CDW announces CFO Albert Miralles will retire in 2027, initiating a carefully planned succession amid strong financial performance and a dynamic IT market.

Despite a revenue dip, Glacier Media's strategic exit from print has ignited a stunning return to profitability, signaling a new era for the data-driven firm.

With a plunging stock price and a new CEO, LifeSpeak is pivoting hard. Can veteran Neil King and a platform promising real ROI finally answer the market's call?

DDC Enterprise reports a 28% revenue surge, but the real story is how its food business funds an ambitious Bitcoin treasury and shareholder value strategy.

The logistics giant's acquisition of SEGRO isn't just about size; it's a strategic move to dominate Europe's most valuable warehouse and data center markets.

Curium's landmark $8 billion acquisition of Lantheus is set to create a global powerhouse in nuclear medicine, reshaping patient care and the competitive landscape.

Private equity giant KKR is acquiring medical device maker Integer in a $5.7B deal, signaling a major investment in the future of outsourced MedTech innovation.

Pathward Financial's stock plunged after its 'green' energy loans soured, sparking a fraud probe. Is this a cautionary tale for the entire ESG movement?

Allied Universal's major Canadian acquisition of SSC signals a market consolidation, while a management buy-out creates a new specialized cyber player.

The energy giant's massive new repurchase authorization highlights robust financial health and a multi-faceted strategy balancing shareholder returns with growth.

Hong Kong-based Fenbo Holdings has 180 days to save its Nasdaq listing. Its sub-$1 stock price reveals deeper issues in manufacturing and global markets.

A year of delays and a stagnant €14.10 offer have ignited shareholder dissent, with Petrus Advisers leading the charge to reject Tata's bid for Iveco.

Karyopharm's stock plummets after a key cancer trial fails, forcing a strategic retreat and a hard pivot toward more promising assets in its pipeline.

With $217M in the bank, SAB Biotherapeutics has silenced liquidity fears. Now, all eyes are on its novel T1D drug and the unproven promise of its cow-powered tech.

Cinemark shattered records with its first-ever billion-dollar quarter, proving strategic investments in premium experiences can defy the streaming era.

Vitesse Energy's 11% dividend yield turns heads, but can its unique non-operator model sustain these payouts? We go beyond the headlines to find out.

A truce between Ashland and activist Ancora brings two new directors and a powerful new committee. This is more than a settlement—it's a deep look into the changing power dynamics between boardrooms and their biggest shareholders.

Hong Kong's Everbright Digital secured new funds for its metaverse ambitions, but a closer look at the deal reveals the harsh realities facing small-cap tech firms.